NeurAxis, Inc. - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
NRXS NYSE American 3841 neuraxis.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for NeurAxis, Inc.

NeurAxis Stock Gains Post Q4 Earnings on Strong Revenue Growth - Mar 24th, 2026 9:09 am
Neuraxis Inc (NRXS) Q4 2025 Earnings Call Highlights: Revenue Growth Amidst Operational Challenges - Mar 19th, 2026 1:02 pm
NeurAxis, Inc. Q4 2025 Earnings Call Summary - Mar 19th, 2026 6:30 am
NeurAxis Reports Strong Fourth Quarter and Full Year 2025 Financial Results - Mar 19th, 2026 5:05 am
NeurAxis to Host Fourth Quarter and Full Year 2025 Results and Business Update Call on Thursday, March 19, 2026 - Mar 12th, 2026 7:00 am
NeurAxis Achieves Major Milestone with AMA Category I CPT® Code Now in Effect, Establishing a Permanent Reimbursement Pathway - Jan 8th, 2026 6:00 am
Top Stock Reports for Meta, Bank of America & Procter & Gamble - Jan 5th, 2026 2:34 pm
NeurAxis Achieves Medical Coverage Policy Milestone, Expanding Access to Approximately 45 million additional Covered Lives - Dec 19th, 2025 6:00 am
NeurAxis Secures Veterans Affairs Federal Supply Schedule Contract, Broadening Access to More Patients with Functional Abdominal Pain - Dec 1st, 2025 5:00 am
NRXS Stock Declines Post Q3 Earnings Despite Continued Revenue Growth - Nov 17th, 2025 10:17 am
NeurAxis Announces New Medical Policy Coverage in Michigan, Adding 566,000 Covered Lives - Nov 12th, 2025 6:00 am
NeurAxis Reports Strong Third Quarter 2025 Financial Results Driven by a 22% Growth in Revenues - Nov 11th, 2025 5:00 am
NeurAxis to Host Third Quarter 2025 Results and Business Update Call on Tuesday, November 11, 2025 - Nov 4th, 2025 6:30 am
NeurAxis Awarded First Ever FDA Clearance for the Treatment of Pain in Functional Dyspepsia (FD) with associated Nausea Symptoms in the Adult Patient Population - Oct 24th, 2025 6:00 am
NeurAxis to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025 - Sep 18th, 2025 6:00 am
The Zacks Analyst Blog Highlights Alphabet, IBM, Merck, SandRidge Energy and NeurAxis - Sep 17th, 2025 3:53 am
Top Research Reports for Alphabet, IBM & Merck - Sep 16th, 2025 2:42 pm
NeurAxis Stock Down Following Q2 Earnings Despite Revenue Growth - Aug 18th, 2025 12:27 pm
NeurAxis Reports Strong Second Quarter 2025 Financial Results Driven by a 46% Growth in Revenues - Aug 12th, 2025 5:00 am
NeurAxis to Host Second Quarter 2025 Results and Business Update Call on Tuesday, August 12, 2025 - Aug 5th, 2025 6:30 am